Skip to main content

View Resource

Published

Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa: a phase 2a randomised, observer-blind trial.
Govender V. The Lancet HIV 2026;:https://doi.org/10.1016/S2352-3018(25)00275-9.
[WHO recommends a boost COVID-19 vaccine dose for people with immunosuppression, including people living with HIV. A single dose of ancestral Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-PN vaccines was safe and induced robust and durable immune responses, regardless of CD4 count and viral suppression. This vaccine strategy should be considered in low-income and middle-income countries.]
Available with an NHS OpenAthens password
Age Groups
Adults
Conditions and Lifestyle Factors
Coronavirus Infections
HIV / AIDS
Settings
World Health
Staff Groups
Immunisation